Aquinox Pharmaceuticals, Inc.


Company Name:
Aquinox Pharmaceuticals, Inc.  
Sector:
Healthcare 
Transaction Type:
Follow-on Offering 
Ticker Symbol:
AQXP 
Deal Amount:
$75.4M
Transaction Date:
9/19/2016 
Transaction Summary:
Aquinox Pharmaceuticals, Inc. raised $75.4 million in its follow-on offering at $12.25 per share. Needham acted as a lead manager on the transaction. The Company‚Äôs underwriters fully exercised their option to purchase an additional 802,500 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Aquinox Pharmaceuticals, Inc. to fund additional clinical development of AQX-1125 and to fund pre-commercial and market assessment activities, research and development costs to advance its pipeline of preclinical product candidates and for working capital and other general corporate purposes. 
Company Description:
Aquinox Pharmaceuticals, Inc. ("Aquinox") (NASDAQ:AQXP) is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox's lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. With a successful Phase 2 clinical trial completed in 2015, Aquinox initiated a Phase 3 trial in 2016 (LEADERSHIP 301) with AQX-1125 for treatment of IC/BPS. Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1. 
Investment Banking